Anti-covid drugs put millions of people at risk

Medicines that came to be highly recommended now leave the most fragile patients in a more delicate situation.

They were, and were, revolutionary medicines. They improved the health status of millions of people – including Donald Trump, then president.

However, there are anti-covid drugswhich came to be highly recommended, which now appear as threats to the health of millions of people in the United States of America.

The notice is made by the portal Politicalwhich leaves two warnings: little or nothing do now, faced with the current variants of the coronavirus and, in addition, are not safe for all patients.

Pills like the famous Paxlovid can be a threat to patients because “mess” with many other medications already prescribed, which patients usually take.

There is a monetary issue holding back the development of new medicines: the federal government no longer funds research in this scope. President Joe Biden has already tried but without success.

Thus, many at-risk patients will run the risk of develop severe cases of covid – and hospitals will be overwhelmed again.

THE COVID-19 hasn’t disappeared, winter started a few days ago and the flu it’s the respiratory syncytial virus attack “seriously”. There are millions of Americans vulnerable to serious illnesses.

The problem

Pills are molecules created in the laboratory to block the entry of a virus into human cells.

But they must bind to the virus’s spike protein to neutralize it – and the many variants of the coronavirus have turned existing pills into something ineffective: another variant, another spike protein.

A problem especially for people most fragilewith a compromised immune system (or since birth, or since undergoing transplants or certain medications): vaccine may not arrive and they would need “reinforcements”.

Reinforcements for treatment and prevention… There is notadmitted the Center for Disease Control and Prevention, in a announcement Published less than two weeks ago.

Congress does nothing, funding doesn’t come in, and the US National Health Service don’t have the resources needed to fund the development of new treatments.

Therefore, and already this winter, the likely scenario is that they have few ways to fight the disease at home.

There are already requests, at the National Institute of Health in the White House itself, for meetings with scientists.

The companies pharmaceutical may be more inclined – financially and practically – to create new antiviral pills, which have fewer interactions with other medications and are easier to administer. Build antivirals that better resist an ever-changing virus.